
FDA scientists flag evidence gaps in peptide deregulation push
FDA scientists say seven peptides being considered for compounding pharmacies lack sufficient human data and may pose safety risks, challenging RFK Jr.'s push to deregulate them; an FDA advisory committee will review the evidence July 23–24, but several peptides have little or no human research, raise concerns about contamination and mislabeling, and the FDA must decide, usually following the panel.










